The rare-disease community offers unique challenges in detection, not only in knowing where to find the often very few patients that exist, but also in playing an outsize role in partnering with HCPs and healthcare facilities in the actual diagnoses of these disease states, which can take years.

Pharming Group’s commercialization and development of an innovative portfolio of protein replacement therapies and precision medicines have seen Q1 YoY revenues grow by 42%.